

Video-assisted thoracic surgery versus open lobectomy for lung cancer: a randomized prospective trial

Published: 24-07-2012

Last updated: 26-04-2024

To compare quality of life, cost-effectiveness and number of dissected mediastinal lymph node as a derivative oncologic outcome between open- and VATS lobectomy.

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Respiratory tract neoplasms
Study type	Interventional

Summary

ID

NL-OMON37381

Source

ToetsingOnline

Brief title

VATS versus open lobectomy

Condition

- Respiratory tract neoplasms

Synonym

lung cancer, pulmonary carcinoma

Research involving

Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Sint Radboud

Source(s) of monetary or material Support: ZonMw subsidie aangevraagd

Intervention

Keyword: lobectomy, thoracoscopic, video-assisted

Outcome measures

Primary outcome

Primary endpoints are postoperative quality of life, number of dissected mediastinal lymph nodes for oncologic staging, hospital length of stay and overall costs.

Secondary outcome

Secondary endpoints include procedural complication rates, pulmonary function and survival.

Study description

Background summary

Surgical lobectomy is the treatment of choice for patients with early stage lung cancer. In some centres, video-assisted thoracic surgery (VATS) lobectomy is preferred, where several other centres hold on to the conventional open lobectomy via a thoracotomy. Although several studies have demonstrated fewer postoperative complications and shorter hospital length of stay for the VATS procedure, others reported concerns regarding oncologic staging. Convincing randomized evidence from the literature is lacking. The aim of this randomized multicentre study is to compare quality of life, oncologic endpoints and cost-effectiveness between VATS- and open (thoracotomy) lobectomy.

Study objective

To compare quality of life, cost-effectiveness and number of dissected mediastinal lymph node as a derivative oncologic outcome between open- and VATS lobectomy.

Study design

A prospective multi-centre randomized trial.

Intervention

One group is assigned to the open procedure: posterolateral thoracotomy for lobectomy with mediastinal lymph node dissection. The other group is assigned to the VATS procedure: thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection.

Study burden and risks

Centres participating in this study currently perform the open- and VATS lobectomy in daily clinical practice. Either intervention therefore does not introduce an extra risk for the patient. Assessment of quality of life and pain scores carry an extra burden for the patient, but are necessary elements to define the difference between open- and VATS lobectomy. There is no direct benefit for patients to participate.

Contacts

Public

Universitair Medisch Centrum Sint Radboud

Geert Grooteplein 10, postbus 9101
6500 HB Nijmegen
NL

Scientific

Universitair Medisch Centrum Sint Radboud

Geert Grooteplein 10, postbus 9101
6500 HB Nijmegen
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Patients selected by multidisciplinary oncologic team to undergo lobectomy
Non-small cell lung carcinoma, pathologically confirmed or strong suspicion based on imaging.
T1 or T2a (≤ 5 cm) on computer tomography (CT).
Primary aim is lobectomy.
Tumor is not in close relation to central structures (main bronchus, pulmonary artery or pulmonary veins) and is surrounded by lung parenchyma (based on CT).
Clinically staged N0 or N1 (lymph nodes), M0 (no distant metastasis) after clinical staging according to the current Dutch guideline (May 2011).

Exclusion criteria

T2b, T3 or T4 tumor (7th guideline TNM classification NSCLC).
Mediastinal lymph node metastasis (N2, N3).
Distant metastasis (M1).
Previous thoracic surgery on same side.
Pneumonectomy as primary aim.

Study design

Design

Study phase:	4
Study type:	Interventional
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	23-05-2013
Enrollment:	160

Type: Actual

Ethics review

Approved WMO	
Date:	24-07-2012
Application type:	First submission
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO	
Date:	13-09-2013
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO	
Date:	03-04-2014
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)
Approved WMO	
Date:	29-07-2014
Application type:	Amendment
Review commission:	CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL40542.091.12